588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)

• Llenalia Garcia-Fernandez,
• Jean Hurteau,
• Lydia Lee,
• Solomon J Lubinga,
• Tilman Payer,
• Meghann Gregg,
• Odette Allonby

Affiliations

Llenalia Garcia-Fernandez

2Parexel, Madrid, Spain

Jean Hurteau

1GSK, Collegeville, PA, USA

Lydia Lee

1GSK, Collegeville, PA, USA

Solomon J Lubinga

1GSK, Collegeville, PA, USA

Tilman Payer

2Parexel, Madrid, Spain

Meghann Gregg

3Parexel, Durham, NC, USA

Odette Allonby

5GSK, Mississauga, ON, Canada